Absci (ABSI) Revenue & Revenue Breakdown
Absci Revenue Highlights
Latest Revenue (Y)
$5.72M
Latest Revenue (Q)
$898.00K
Absci Revenue by Period
Absci Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $5.72M | -0.50% |
2022-12-31 | $5.75M | 20.18% |
2021-12-31 | $4.78M | 0.04% |
2020-12-31 | $4.78M | 132.04% |
2019-12-31 | $2.06M | - |
Absci Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $898.00K | 165.68% |
2023-12-31 | $338.00K | -54.57% |
2023-09-30 | $744.00K | -77.90% |
2023-06-30 | $3.37M | 165.33% |
2023-03-31 | $1.27M | -18.50% |
2022-12-31 | $1.56M | -34.28% |
2022-09-30 | $2.37M | 136.43% |
2022-06-30 | $1.00M | 22.34% |
2022-03-31 | $819.00K | -43.60% |
2021-12-31 | $1.45M | -5.65% |
2021-09-30 | $1.54M | 111.40% |
2021-06-30 | $728.00K | -31.51% |
2021-03-31 | $1.06M | -61.03% |
2020-12-31 | $2.73M | 197.82% |
2020-09-30 | $916.00K | 62.41% |
2020-06-30 | $564.00K | -1.40% |
2020-03-31 | $572.00K | - |
Absci Revenue Breakdown
Absci Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Jun 21 |
---|---|
Collaborative Revenue | $136.00K |
Technology Development Revenue | $592.00K |
Absci Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Jun 21 |
---|---|
Collaborative Revenue | $136.00K |
Technology Development Revenue | $592.00K |
Absci Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
DTIL | Precision BioSciences | $48.73M | $49.90M |
RXRX | Recursion Pharmaceuticals | $44.58M | $13.79M |
CRBU | Caribou Biosciences | $34.48M | $3.46M |
VECT | VectivBio | $27.34M | $676.00K |
RLAY | Relay Therapeutics | $25.55M | - |
EXAI | Exscientia | $24.96M | $5.29M |
AFMD | Affimed | $8.28M | $155.00K |
ABSI | Absci | $5.72M | $898.00K |
XFOR | X4 Pharmaceuticals | - | $563.00K |
AVRO | AVROBIO | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ZURA | Zura Bio | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
GRPH | LENZ Therapeutics | - | - |
ELEV | Elevation Oncology | - | - |
CFRX | ContraFect | - | - |
SANA | Sana Bio | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
ABSI Revenue FAQ
What is Absci’s yearly revenue?
Absci's yearly revenue for 2023 was $5.72M, representing a decrease of -0.50% compared to 2022. The company's yearly revenue for 2022 was $5.75M, representing an increase of 20.18% compared to 2021. ABSI's yearly revenue for 2021 was $4.78M, representing an increase of 0.04% compared to 2020.
What is Absci’s quarterly revenue?
Absci's quarterly revenue for Q1 2024 was $898K, a 165.68% increase from the previous quarter (Q4 2023), and a -29.24% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $338K, a -54.57% decrease from the previous quarter (Q3 2023), and a -78.29% decrease year-over-year (Q4 2022). ABSI's quarterly revenue for Q3 2023 was $744K, a -77.90% decrease from the previous quarter (Q2 2023), and a -68.59% decrease year-over-year (Q3 2022).
What is Absci’s revenue growth rate?
Absci's revenue growth rate for the last 3 years (2021-2023) was 19.57%, and for the last 5 years (2019-2023) was 177.57%.